Pattern recognition system based on support vector machines: HIV-1 integrase inhibitors application

Support Vector Machines (SVM) represent one of the most promising Machine Learning (ML) tools that can be applied to develop a predictive Quantitative Structure-Activity Relationship (QSAR) models using molecular descriptors. The performance and predictive power of support vector machines (SVM) for regression problems in quantitative structure-activity relationship were investigated. The SVM results are superior to those obtained by artificial neural network and multiple linear regression. These results indicate that the SVM model with the kernel radial basis function can be used as an alternative tool for regression problems in quantitative structure-activity relationship. Keywords : Support Vector Machines; Artificial Neural Network; Quantitative Structure-Activity Relationship.

[1]  Johann Gasteiger,et al.  Neural Networks for Chemists: An Introduction , 1993 .

[2]  S. Swaminathan,et al.  Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. , 2008, Journal of molecular biology.

[3]  Corinna Cortes,et al.  Support-Vector Networks , 1995, Machine Learning.

[4]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[5]  A. Parrill,et al.  QSAR development to describe HIV-1 integrase inhibition , 2000 .

[6]  L. Menéndez-Arias,et al.  HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. , 2008, Trends in pharmacological sciences.

[7]  D. Villemin,et al.  Use of a neural network to determine the boiling point of alkanes , 1994 .

[8]  Vladimir N. Vapnik,et al.  The Nature of Statistical Learning Theory , 2000, Statistics for Engineering and Information Science.

[9]  Christopher J. C. Burges,et al.  A Tutorial on Support Vector Machines for Pattern Recognition , 1998, Data Mining and Knowledge Discovery.

[10]  V. Ravichandran,et al.  QSAR study of substituted 1,3,4-oxadiazole naphthyridines as HIV-1 integrase inhibitors. , 2010, European journal of medicinal chemistry.

[11]  Paola Gramatica,et al.  The Importance of Being Earnest: Validation is the Absolute Essential for Successful Application and Interpretation of QSPR Models , 2003 .

[12]  N. Dessalew.  QSAR Study on Piperidinecarboxamides as Antiretroviral Agents: An Insight Into the Structural Basis for HIV Coreceptor Antagonist Activity , 2008 .

[13]  L Douali,et al.  Comparative QSAR based on neural networks for the anti-HIV activity of HEPT derivatives. , 2003, Current pharmaceutical design.

[14]  Dayou Liu,et al.  A support vector machine classifier with rough set-based feature selection for breast cancer diagnosis , 2011, Expert Syst. Appl..

[15]  Paola Gramatica,et al.  Introduction General Considerations , 2022 .

[16]  Chih-Jen Lin,et al.  LIBSVM: A library for support vector machines , 2011, TIST.

[17]  Wenjian Wang,et al.  Determination of the spread parameter in the Gaussian kernel for classification and regression , 2003, Neurocomputing.

[18]  Xue-feng Yan,et al.  Adaptive weighted least square support vector machine regression integrated with outlier detection and its application in QSAR , 2009 .

[19]  V. Planelles,et al.  HIV-1 Vpr: mechanisms of G2 arrest and apoptosis. , 2008, Experimental and molecular pathology.

[20]  David M. Skapura,et al.  Neural networks - algorithms, applications, and programming techniques , 1991, Computation and neural systems series.

[21]  Nasser Hassan Sweilam,et al.  Support vector machine for diagnosis cancer disease: A comparative study , 2010 .

[22]  EAGLES report on HIV/AIDS research. , 2008, New biotechnology.

[23]  Alexander Golbraikh,et al.  Predictive QSAR modeling workflow, model applicability domains, and virtual screening. , 2007, Current pharmaceutical design.

[24]  E. Garvey,et al.  1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position. , 2009, Bioorganic & medicinal chemistry letters.

[25]  P. Lusso,et al.  Rational design of novel HIV-1 entry inhibitors by RANTES engineering. , 2008, Vaccine.